A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

Hundreds of Australians with breast and prostate cancer will benefit from new treatments being added to the Pharmaceutical ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Researchers at UCLA have unveiled startling findings using PSMA-PET imaging that reveal nearly half of patients diagnosed ...

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once ...

The past fifteen years, for a family in Lagos, have been marked by an unrelenting pattern of cancer diagnoses occurring ...

The study found that Focal One's treatment methods match up with the gold star standard of surgery, and improve quality of life outcomes.

Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

Prostate cancer is one of those things most men don’t think about until it hits close to home.  But it’s common, affecting millions—and early detection can save lives. The cancer itself can be sneaky, ...

King Charles III was diagnosed with cancer earlier this year after a hospital visit for an enlarged prostate. This is how treatment is going.